Analyst Price Target is $17.00
▲ +128.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for POINT Biopharma Global in the last 3 months. The average price target is $17.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 128.49% upside from the last price of $7.44.
Current Consensus is
The current consensus among 5 contributing investment analysts is to hold stock in POINT Biopharma Global. This rating has held steady since November 2021, when it changed from a Buy consensus rating.
POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.